Skip to main navigation
  • US
    • 中文

Home

  • BeiGene

Main navigation

  • About
    • Our Story
    • Leadership Team
      • Meet More of Our Team
    • Focus on Quality
    • Who We Are
    • Ethics
  • Science & Pipeline
    • Research & Development
    • Manufacturing
    • Pipeline
      • Zanubrutinib
      • Tislelizumab
      • Pamiparib
      • Lifirafenib
      • Preclinical Candidates
  • Products
  • BeiGene
  • Partnering
    • Partnering with BeiGene
    • Doing Business in China
  • Patients
    • Clinical Trials
    • Access to Investigational Medicines
  • Careers
    • Culture & Benefits
    • Job Opportunities
  • Investors
    • NASDAQ investors
    • HKEX investors
  • Media
  • Contact

Partnerships

Nasdaq Investors
IR Menu
  • Overview
  • Stock
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financials
    • SEC Filings
    • Annual Reports
    • Tax Information
    • Shareholder Meeting
  • News & Events
    • Press Releases
    • Events & Calendar
    • Investor Presentation
    • Investor Video
  • Governance
    • Documents & Charters
    • Committee Composition
    • ESG Report
  • IR Resources
    • Investor Services
    • FAQs
    • IR Contact
    • Email Alerts
  • En
  • 中文
  • SEC Filings
  • Annual Reports
  • Tax Information
  • Shareholder Meeting

Shareholder Meeting

Shareholder Meeting

October 9, 2020
Proxy Statement for 2020 Extraordinary General Meeting of Shareholders 796.2 KB
October 9, 2020
Form of Proxy for 2020 Extraordinary General Meeting of Shareholders 91.1 KB
April 29, 2020
Proxy Statement for 2020 Annual General Meeting of Shareholders 435.9 KB
April 29, 2020
Form of Proxy for 2020 Annual General Meeting of Shareholders 150.6 KB

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

Accept

Find Out More

  • Email alerts

    Sign up to receive e-mail alerts

  • Leadership Team

    Our cooperative and non-heirarchical culture will continue to be instrumental to our success.

  • Investor Contact

    For IR related inquiries.

  • RSS Feeds

  • Email Alerts

  • Print Page

Site Navigation

  • About
  • Science & Pipeline
  • Products
  • BeiGene
  • Partnering
  • Patients
  • Careers

© 2021 BeiGene LTD. All Rights Reserved.

Footer

  • Investors
  • Media
  • Contact
  • Site Map
  • Terms of Use
  • Privacy Policy
❌

BeiGene, Ltd. (“BeiGene”) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.

BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor). BeiGene has also in-licensed six drugs and drug candidates, including three marketed drugs in China ABRAXANE®, REVLIMID® and VIDAZA® under an exclusive license from Celgene Corporation, and two clinical-stage drug candidates with development and commercialization rights in China and other selected countries in the Asia-Pacific region.

BeiGene was established in Beijing in 2010 and listed on the U.S. NASDAQ Global Select Market in February 2016. As of February 27, 2019, the Company had a global team of over 2,200 employees. BeiGene operates as a fully-integrated global biotechnology company with broad capabilities, both in China and globally, spanning research, clinical development, manufacturing and commercialization.

❌

Widget - Stock Chart